Tenderwize
Wróć do wyszukiwania

Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2027 · 430 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Brimonidin (amtlicher ATC-Code: S01EC24)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...

The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for Brinzolamid/Brimonidin.
  • Open-House model: any interested company may join during the participation period if it meets and accepts the conditions.
Pokaż pełne podsumowanie

This is an Open-House pharmaceutical supply arrangement for the active substance Brinzolamid/Brimonidin (ATC S01EC24) with AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation is handled electronically via DTVP, but submission is not via the bidder tool; the participation documents must be obtained from the project room after access approval. The notice is highly document-dependent, but the extracted procurement documents are not available beyond the XML notice text, so some submission details remain incomplete.

Ryzyka

The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...

The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must declare no mandatory or discretionary exclusion grounds using the provided self-declaration form.

Administrative

  • A declaration regarding Russia sanctions compliance is required using the specified form.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin

Non-exclusive supply/framework-style Open-House agreement for pharmaceutical products containing Brinzolamid/Brimonidin (ATC S01EC24). Scope is the conclusion of rebate agreements with all eligible pharmaceutical companies. Place of performance is Dresden, Germany, with performance also linked to Saxony and Thuringia as stated in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Oct 2025 - Oct 2027

Kategoria

Pharmaceutical products

Termin

Deadline Oct 31, 2027

Szczegóły zamówienia

Data publikacji
24 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
551011-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3